

PRODUCT INFORMATION

Common Name	SC0001-SCX,SC0002,sc0001-SCX
Conjugate	Unconjugated
Synonyms	SCD01
Applications	ELISA, Flow Cyt
Recommended Dilutions	ELISA 1:5000-10000, Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
lgG type	lgG1
Reactivity	Human
Target	DLL3
Uniprot ID	Q9NYJ7
Description	Anti-DLL3(Rovalpituzumab biosimilar) mAb
Delivery	In Stock
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

Email: info@dimabio.com Website: www.dimabio.com



Cat. No. BME100068






Figure 1. Flow cytometry analysis with Anti-DLL3 (Rovalpituzumab biosimilar) mAb 15 µg/ml on Expi293 cells transfected with Human DLL3 (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram).

Anti-DLL3(Rovalpituzumab biosimilar) mAb ELISA

0.2 µg of Human DLL3, hFc tagged protein per well




Figure 2. ELISA plate pre-coated by 2 μ g/mL (100 μ L/well) Human DLL3 Protein, hFc Tag (PME100607) can bind Anti-DLL3(Rovalpituzumab biosimilar) mAb (BME100068) in a linear range of 0.64–80 ng/mL. In order to specifically detect BME100068, mouse anti-human Fab-specific antibody was used as detection antibody.

Email: info@dimabio.com Website: www.dimabio.com

